WALTHAM, MA • 2022-11-03

BostonGene Announces Abstract Presentation at the Association for Molecular Pathology 2022 Annual Meeting

5 min to read

BostonGene to Showcase Cancer Diagnostic and Treatment Recommendation Test
WALTHAM, MA, November 3, 2022

BostonGene today announced that an abstract has been accepted for online publication for the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo, which will be held November 3 - 5, 2022, at the Phoenix Convention Center in Phoenix, AZ.  BostonGene will also exhibit at booth 943.

The abstract, Co-occurrence of KRAS Q61K with Synonymous Mutations and Their Effect on RNA Expression, demonstrates the value of next-generation sequencing (NGS) in identifying the co-occurrence of KRAS p.Q61K with synonymous mutations and underscores the importance of RNA sequencing (RNA-seq) to further analyze their effects on gene expression and isoform composition.  The research, conducted with Massachusetts General Hospital, will be available online only in The Journal of Molecular Diagnostics.

BostonGene will showcase its innovative AI-based molecular and immune profiling platform for the discovery of significant correlations among tumor genomics, a patient’s immune system and the effectiveness of all available approved and investigational treatments, which leads to advances in personalized medicine and dramatically improved patients clinical outcomes. The BostonGene Tumor PortraitTM test uses DNA whole exome (WES) and RNA transcriptome (RNAseq) sequencing to detect genomic alterations such as single nucleotide variants (SNVs), indels, copy number alterations (CNAs), tumor mutational burden (TMB), microsatellite instability (MSI), expressed fusions, and frameshifts, and interrogates the expression levels of more than 20,000 genes, to identify actionable targets to inform treatment decision-making.

Please visit the AMP 2022 Annual Meeting & Expo website for more information.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director